Genelux (GNLX) Competitors $5.44 +0.16 (+3.03%) Closing price 04:00 PM EasternExtended Trading$5.60 +0.16 (+2.92%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. PRME, IOVA, RZLT, NRIX, DAWN, AKBA, OLMA, TYRA, TERN, and TBPHShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), Rezolute (RZLT), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Prime Medicine Iovance Biotherapeutics Rezolute Nurix Therapeutics Day One Biopharmaceuticals Akebia Therapeutics Olema Pharmaceuticals Tyra Biosciences Terns Pharmaceuticals Theravance Biopharma Prime Medicine (NASDAQ:PRME) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Does the media prefer PRME or GNLX? In the previous week, Prime Medicine and Prime Medicine both had 3 articles in the media. Genelux's average media sentiment score of 0.83 beat Prime Medicine's score of 0.32 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, PRME or GNLX? Genelux has lower revenue, but higher earnings than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$2.98M287.65-$195.88M-$1.56-4.08Genelux$10K20,546.88-$29.87M-$0.86-6.33 Which has more volatility & risk, PRME or GNLX? Prime Medicine has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Genelux has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Do institutionals & insiders believe in PRME or GNLX? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 8.8% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate PRME or GNLX? Genelux has a consensus target price of $20.33, indicating a potential upside of 273.77%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is PRME or GNLX more profitable? Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Genelux's return on equity of -107.47% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime Medicine-4,016.83% -156.16% -64.41% Genelux N/A -107.47%-83.14% SummaryGenelux beats Prime Medicine on 9 of the 15 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.44M$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-6.3322.7785.3627.36Price / Sales20,546.88485.21607.16135.99Price / CashN/A46.7037.4661.86Price / Book7.1610.5512.426.81Net Income-$29.87M-$52.58M$3.32B$276.80M7 Day Performance14.53%1.09%1.01%0.27%1 Month Performance38.78%16.09%10.75%8.31%1 Year Performance70.53%18.41%76.20%35.60% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.3969 of 5 stars$5.44+3.0%$20.33+273.8%+99.2%$199.44M$10K-6.3310Positive NewsPRMEPrime Medicine0.645 of 5 stars$5.65-0.5%N/AN/A$764.38M$2.98M-3.62N/AGap UpIOVAIovance Biotherapeutics4.5453 of 5 stars$2.14+1.9%$11.90+456.1%-78.3%$759.89M$164.07M-1.74500RZLTRezolute2.7481 of 5 stars$8.07-2.4%$14.50+79.7%+76.2%$751.15MN/A-8.3240NRIXNurix Therapeutics1.8783 of 5 stars$9.72-0.4%$27.86+186.6%-63.5%$750.38M$54.55M-3.27300Earnings ReportAnalyst ForecastDAWNDay One Biopharmaceuticals3.1106 of 5 stars$7.19-0.7%$25.29+251.7%-50.7%$741.61M$131.16M-7.5760News CoverageAnalyst UpgradeAKBAAkebia Therapeutics3.4747 of 5 stars$2.78+1.1%$6.75+142.8%+111.4%$729.15M$160.18M-16.35430News CoverageOLMAOlema Pharmaceuticals2.5584 of 5 stars$10.75+1.7%$23.33+117.1%-8.4%$725.47MN/A-5.4370TYRATyra Biosciences2.0145 of 5 stars$14.36+6.2%$31.86+121.8%-36.8%$720.58MN/A-8.0720TERNTerns Pharmaceuticals3.9223 of 5 stars$8.20+0.6%$15.49+88.9%+6.0%$713.22MN/A-7.8840Analyst ForecastTBPHTheravance Biopharma3.0015 of 5 stars$13.92-0.5%$23.00+65.2%+68.3%$704.55M$64.38M58.00110 Related Companies and Tools Related Companies Prime Medicine Alternatives Iovance Biotherapeutics Alternatives Rezolute Alternatives Nurix Therapeutics Alternatives Day One Biopharmaceuticals Alternatives Akebia Therapeutics Alternatives Olema Pharmaceuticals Alternatives Tyra Biosciences Alternatives Terns Pharmaceuticals Alternatives Theravance Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
